vimarsana.com

Latest Breaking News On - National organ program - Page 1 : vimarsana.com

TransMedics Stock Skyrockets, Analysts Call It One Of The Best Organic Growth Stories - TransMedics Gr (NASDAQ:TMDX)

TransMedics shines with Q1 EPS at $0.35, and sales soared to $96.9 million. Fiscal 2024 revenue outlook raised to $390 million-$400 million. Analysts hail TransMedics' organic growth and strong market position, praising its innovative solutions and promising prospects.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.